Global liver societies unite on a single ACLF definition
-
November 20
The 81-statement consensus sets liver failure at a bilirubin of at least 5 mg/dL and an INR of at least 1.5 and grades severity by the number of other organs showing dysfunction or failure.
BROWSE BY TOPICS
Substance use disorders in gastroenterology and hepatology: A practical guide for the general gastroenterologist
-
August 3
-
by Isabelle S. Byers, MD, Michelle Russin, MD, Sasha Deutsch-Link, MD, MSCR
GI and liver complications often bring these patients in first, and the authors say gastroenterologists are well placed to screen and treat.
Bridging the rural divide: Building a motility center in a critical access hospital
-
August 3
-
by Amber Charoen, MD, W. Michael McDonnell, MD, AGAF
“If large urban centers can run comprehensive motility labs, why can't a critical access hospital?”
Is professional coaching worth it? A practical guide for early-career gastroenterologists
-
August 3
-
by Mariam Naveed, MD, FACG, Kathryn E. Hutchins, MD, FACG
Two program directors on why coaching belongs at the start of a GI career, not after something has already gone wrong.
The Latest
Global liver societies unite on a single ACLF definition
-
by Doug Brunk
The 81-statement consensus sets liver failure at a bilirubin of at least 5 mg/dL and an INR of at least 1.5 and grades severity by the number of other organs showing dysfunction or failure.
A global consensus definition of acute-on-chronic liver failure: A major step forward for hepatology
-
by Brian Kim, MD, FACG, FAASLD
The collaboration behind the new ACLF definition could serve as a model for other areas of medicine.
Routine labs flag nearly 1 in 4 patients in Stockholm as high risk for MASH
-
by Julie Greenbaum
The five-year rate of major liver events in that group was 2%, and researchers cautioned that the score may overestimate fibrotic MASH.
Neoadjuvant nivolumab plus ipilimumab reaches 100% 3-year disease-free survival in dMMR colon cancer trial
-
by Meg Barbor
All 111 patients in the per-protocol analysis were alive and disease-free at a median of nearly five years after surgery, though the single-arm trial had no control group.
HCC surveillance may be cost-effective at lower incidence in alcohol-associated cirrhosis
-
by Meg Barbor
In a U.S. modeling study, twice-yearly ultrasound plus AFP was cost-effective in both active drinkers and abstinent patients.
Esophagus
Liver
Small bowel
Stomach
Obesity
Alcohol-related liver disease
Biliary tract cancer
Colorectal cancer
Esophageal cancer
Liver cancer
Celiac disease
Diarrhea and constipation
Diet and nutrition
Eosinophilic GI diseases
Eosinophilic esophagitis
Hepatic encephalopathy
IBD
Crohn's disease
Ulcerative colitis
IBS
Infections
C. diff
MASLD and MASH
Short bowel syndrome
Pancreatic diseases and conditions
GERD and Barrett’s esophagus
Career & professional development
Diversity, equity, and inclusion
Health, wellness, and burnout
Patient advocacy and equity
Practice management
Coding, coverage, and reimbursement
Technology & innovation
Endoscopy